TGF-β in cancer and as a therapeutic target

Biochemical Pharmacology

Volumn 72, Issue 5, 2006, Pages 523-529

  Pinkas, Jan ^a   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Breast cancer; Prostate cancer; TGF ; Transforming growth factor beta

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; METELIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; MONOCLONAL ANTIBODY 2G7; SD 208; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; LUNG METASTASIS; MESOTHELIOMA; MICROSATELLITE INSTABILITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCAR FORMATION; SCLERODERMA; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 33746763680     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.03.004     Document Type: Note

References (63)

1. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
2. Chambers A.F., Groom A.C., and MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2 (2002) 563-572
3. Siegel P.M., and Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3 (2003) 807-821
4. Bierie B., and Moses H.L. TGF-β and cancer. Cytokine Growth Factor Rev 17 (2006) 29-40
5. Gorska A.E., Jensen R.A., Shyr Y., Aakre M.E., Bhowmick N.A., and Moses H.L. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol 163 (2003) 1539-1549
6. Engle S.J., Hoying J.B., Boivin G.P., Ormsby I., Gartside P.S., and Doetschman T. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59 (1999) 3379-3386
7. Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H., et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86 (1996) 543-552
8. Levy L., and Hill C.S. Alterations in compoents of the TGF-b superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17 (2006) 41-58
9. Shu X.O., Gao Y.T., Cai Q., Pierce L., Cai H., Ruan Z.X., et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res 64 (2004) 836-839
10. Pasche B., Kaklamani V., Hou N., Young T., Rademaker A., Peterlongo P., et al. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol 22 (2004) 756-758
11. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21 (2003) 21-32
12. Janda E., Lehmann K., Killisch I., Jechlinger M., Herzig M., Downward J., et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156 (2002) 299-313
13. Gorelik L., and Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2 (2002) 46-53
14. Shah A.H., Tabayoyong W.B., Kimm S.Y., Kim S.J., Van Parijs L., and Lee C. Reconstitution of lethally irradiated adult mice with dominant negative TGF-beta type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol 169 (2002) 3485-3491
15. Meidenbauer N., Zippelius A., Pittet M.J., Laumer M., Vogl S., Heymann J., et al. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 64 (2004) 6319-6326
16. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., and Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9 (2003) 606-612
17. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
18. Somasundaram R., Jacob L., Swoboda R., Caputo L., Song H., Basak S., et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62 (2002) 5267-5272
19. Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 173 (2004) 6526-6531
20. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7 (2001) 1118-1122
21. Shah A.H., Tabayoyong W.B., Kundu S.D., Kim S.J., Van Parijs L., Liu V.C., et al. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res 62 (2002) 7135-7138
22. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198 (2003) 1741-1752
23. Lee J.C., Lee K.M., Kim D.W., and Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172 (2004) 7335-7340
24. Takayama T., Morelli A.E., Onai N., Hirao M., Matsushima K., Tahara H., et al. Mammalian and viral IL-10 enhance C{single bond}C chemokine receptor 5 but down-regulate C{single bond}C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J Immunol 166 (2001) 7136-7143
25. Kao J.Y., Gong Y., Chen C.M., Zheng Q.D., and Chen J.J. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 170 (2003) 3806-3811
26. Kong F.M., Anscher M.S., Murase T., Abbott B.D., Iglehart J.D., and Jirtle R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 222 (1995) 155-162
27. Xie W., Mertens J.C., Reiss D.J., Rimm D.L., Camp R.L., Haffty B.G., et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 62 (2002) 497-505
28. Ivanovic V., Todorovic-Rakovic N., Demajo M., Neskovic-Konstantinovic Z., Subota V., Ivanisevic-Milovanovic O., et al. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 39 (2003) 454-461
29. MacCallum J., Keen J.C., Bartlett J.M., Thompson A.M., Dixon J.M., and Miller W.R. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. Br J Cancer 74 (1996) 474-478
30. Lafon C., Mazars P., Guerrin M., Barboule N., Charcosset J.Y., and Valette A. Early gene responses associated with transforming growth factor-beta 1 growth inhibition and autoinduction in MCF-7 breast adenocarcinoma cells. Biochim Biophys Acta 1266 (1995) 288-295
31. Arteaga C.L., Koli K.M., Dugger T.C., and Clarke R. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 91 (1999) 46-53
32. Buck M.B., Fritz P., Dippon J., Zugmaier G., and Knabbe C. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 10 (2004) 491-498
33. Slamon D.J. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest 8 (1990) 253
34. Siegel P.M., Shu W., Cardiff R.D., Muller W.J., and Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100 (2003) 8430-8435
35. Muraoka-Cook R.S., Kurokawa H., Koh Y., Forbes J.T., Roebuck L.R., Barcellos-Hoff M.H., Moody S.E., Chodosh L.A., and Arteaga C.L. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64 (2004) 9002-9011
36. Tang B., Vu M., Booker T., Santner S.J., Miller F.R., Anver M.R., et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112 (2003) 1116-1124
37. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 (2004) 1655-1664
38. Kakonen S.M., Selander K.S., Chirgwin J.M., Yin J.J., Burns S., Rankin W.A., et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277 (2002) 24571-24578
39. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115 (2005) 44-55
40. Bello-DeOcampo D., and Tindall D.J. TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets 4 (2003) 197-207
41. Shariat S.F., Menesses-Diaz A., Kim I.Y., Muramoto M., Wheeler T.M., and Slawin K.M. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 63 (2004) 1191-1197
42. Dallas S.L., Zhao S., Cramer S.D., Chen Z., Peehl D.M., and Bonewald L.F. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 202 (2005) 361-370
43. Shariat S.F., Kattan M.W., Traxel E., Andrews B., Zhu K., Wheeler T.M., et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10 (2004) 1992-1999
44. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
45. Webber M.M., Quader S.T., Kleinman H.K., Bello-DeOcampo D., Storto P.D., Bice G., et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 47 (2001) 1-13
46. Teicher B.A., Kakeji Y., Ara G., Herbst R.S., and Northey D. Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 11 (1997) 453-461
47. Matthews E., Yang T., Janulis L., Goodwin S., Kundu S.D., Karpus W.J., et al. Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. Br J Cancer 83 (2000) 519-525
48. San Francisco I.F., DeWolf W.C., Peehl D.M., and Olumi A.F. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer 112 (2004) 213-218
49. Tuxhorn J.A., McAlhany S.J., Dang T.D., Ayala G.E., and Rowley D.R. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62 (2002) 3298-3307
50. Tuxhorn J.A., McAlhany S.J., Yang F., Dang T.D., and Rowley D.R. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62 (2002) 6021-6025
51. Yingling J.M., Blanchard K.L., and Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Dis 3 (2004) 1011-1022
52. Teicher B.A. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20 (2001) 133-143
53. Ohmori T., Yang J.L., Price J.O., and Arteaga C.L. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res 245 (1998) 350-359
54. Teicher B.A., Herman T.S., Holden S.A., Wang Y.Y., Pfeffer M.R., Crawford J.W., et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247 (1990) 1457-1461
55. Teicher B.A., Holden S.A., Ara G., and Chen G. Transforming growth factor-beta in in vivo resistance. Cancer Chemother Pharmacol 37 (1996) 601-609
56. Teicher B.A., Ikebe M., Ara G., Keyes S.R., and Herbst R.S. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 11 (1997) 463-472
57. Yang Y.A., Dukhanina O., Tang B., et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109 (2002) 1607-1615
58. Muraoka R.S., Dumont N., Ritter C.A., et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration and metastases. J Clin Invest 109 (2002) 1551-1559
59. Suzuki E., Kapoor V., Cheung H.K., et al. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 10 (2004) 5907-5918
60. Peng S.B., Yan L., Xia X., Watkins S.A., Brooks H.B., Beight D., et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their of the epithelial-mesenchymal transition. Biochemistry 44 (2005) 2293-2304
61. Singh J., Ling L.E., Sawyer J.S., Lee W.C., Zhang F., and Yingling J.M. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TGFbetaRI (ALK5). Curr Opin Drug Dis Dev 7 (2004) 437-445
62. Subramanian G., Schwarz R.E., Higgins L., et al. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinboma cells inhibits their invasive phenotype. Cancer Res 64 (2004) 5200-5211
63. Uhl M., Aulwurm S., Wischhusen J., et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64 (2004) 7954-7961